Dennis Gillings, PhD, Executive Chairman of Quintiles, has been appointed the first world dementia envoy.
Dennis Gillings, PhD, Executive Chairman of Quintiles, has been appointed the first world dementia envoy, according to reports on Friday in the UK media. Gillings plans to create a World Dementia Council to stimulate innovation and development of treatment for those with dementia.
The appointment, announced by Prime Minister David Cameron, follows an agreement between the G8 countries at a dementia summit in London in December, noted an article on the BBC news web site.
Gillings founded Quintiles in 1982, which grew out of his consulting activities with the pharmaceutical industry, and he took the company public on NASDAQ in 1994 and led its privatization in 2003. He served for more than 15 years as a professor at the University of North Carolina at Chapel Hill and received the Honorary Degree of Doctor of Science in May 2001. Also, he was the founding Chairman of the Association of Clinical Research Organizations, a Washington-based trade group formed in 2002.
Speaking for the opposition to the UK Government, Liz Kendall, the UK Labor Party’s shadow minister for care and older people, said she supported the Prime Minister's commitment to dementia research, but warned that more needed to be done to help those struggling with dementia now.
She told the BBC: "£2.7 billion ($4.51 billion) has been cut from council care budgets under this government, hitting the quality of life of hundreds of thousands of people with dementia and their families. The Prime Minister cannot credibly claim to show leadership on dementia unless he tackles poor care standards, like the increasing number of 15-minute home visits which are barely enough time to make a cup of tea, let alone help a frail, elderly person with dementia get up, washed, dressed and fed."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.